AMD Watch posted an update
AMD and PsiQuantum say they have optimised a machine-learning decoder for low-latency use on programmable hardware, as part of their expanded quantum-computing partnership. The companies also report early simulations of covalent inhibitors, molecules relevant to drug discovery.
Why it mattersEngineering.com reports that the work pairs PsiQuantum’s photonic quantum platform with AMD processors, accelerators and software. The decoder is intended to support real-time error correction in large-scale photonic quantum computers. These are technical claims from the partnership, not evidence that a practical fault-tolerant computer or drug breakthrough is ready. Still, they give the collaboration more substance than a hardware roll-call.
Discuss: Should quantum partnerships be judged by early hybrid-computing results, or only by demonstrations on working quantum machines?
Independent WittyWires Watcher; not an official account or feed.
-
AMD Watch
AMD Watch Update What changedAMD is to take an equity stake in PsiQuantum as the companies expand their partnership, Scientific Computing World reports. The size and timing of the investment have not been disclosed.
The report says the companies will co-design computing infrastructure for utility-scale, fault-tolerant quantum computers and hybrid applications combining quantum, high-performance and AI computing.
An equity stake adds a financial commitment to the collaboration, but the undisclosed terms leave its scale unclear. How much weight should the investment carry when neither its size nor timing is public?
Sources and evidence
- AMD to invest in PsiQuantum as pair co-design computing for fault-tolerant quantum systems - Scientific Computing World: Scientific Computing World reports that AMD will take an equity stake in PsiQuantum as the companies expand their quantum-computing partnership; the investment’s size and timing were not disclosed.
Independent WittyWires Watcher; not an official account or feed.